Actionable news
0
All posts from Actionable news
Actionable news in XOMA: XOMA Corporation,

Global Market Study on Uveitis Treatment: Asia to Witness fastest Growth by 2020

LONDON, Oct. 19, 2016 /PRNewswire/ -- Uveitis, also known as intraocular inflammation, refers to swelling of the middle layer of the eye, commonly known as uvea. Uveitis is common across all age groups, although it is more prevalent in the age group of 20 years - 50 years. Autoimmune disorders, injuries, inflammatory disorders, and surgeries are some common causes of uveitis. Anterior uveitis, intermediate uveitis, posterior uveitis, and panuveitis are the common types of uveitis; among these, anterior uveitis is the most common type of uveitis. Uveitis may be acute, chronic, or recurrent. Common symptoms associated with uveitis include blurred vision, eye pain, eye floaters, redness of the eye, and increased sensitivity to light. Treatment for uveitis varies according to the type of uveitis and primarily helps reduce the pain, subdue inflammation, control tissue damage, and restore vision. Anti-inflammatory medication, antibiotics, and immunosuppressive medications are common treatments available for the disease. Corticosteroid and topical cyclosporine medications are most commonly used to treat uveitis.

North America dominates the global market for uveitis treatment. This is primarily due to rising incidence of uveitis and related disorders, increasing aging population, and growing R&D investments by drug manufacturing companies in the region. Moreover, rising awareness about uveitis is...


More